On Tuesday, August 11, 2009, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve replaced at Ochsner Medical Center using the same technique as angioplasty, a far cry from the traditional open heart procedure. Patients who are considered high-risk or non-operable for conventional open heart valve surgery now have a potential new research option available regionally only through The John Ochsner Heart & Vascular Institute. Ochsner Medical Center is the only hospital in the Gulf South selected to participate as an FDA investigative site in the PARTNER (Placement of AoRTic traNscathetER valves) clinical trial, evaluating the Edwards SAPIEN transcatheter aortic heart valve in patients who are at high risk for open heart surgery and surgical valve repair.
WHAT: Data from late-breaking clinical trials of new interventional techniques and devices will be released at TCT 2009 - Transcatheter Cardiovascular Therapeutics - the global annual scientific symposium of the Cardiovascular Research Foundation. Researchers will present a variety of new data that promises to advance the field of interventional cardiology. The TCT 2009 final program is now available at: http://www.tctconference.com/pdf/tct2009-final-program.pdf. The program is also now searchable online by presentations and speakers at: http://www.tctconference.com/program/program-search.html. WHEN: The TCT Scientific Symposium will be held September 21-25, 2009.
Wnk1 is Critical in Angiogenesis and Heart Development A group led by Dr. Chou-long Huang at the University of Texas Southwestern Medical Center in Dallas, Texas have discovered that the protein Wnk1 (with-no-lysine (K)-1) is critical in angiogenesis and heart development. They present these findings in the September 2009 issue of the American Journal of Pathology. Angiogenesis is the formation of blood vessels in organs. However, the molecular mechanisms that regulate blood vessel and heart development, particularly the differentiation of arteries and veins, remain unclear. Wnk1 is required for normal development; yet, its role in vascular development remains poorly characterized.
ATS Medical Announces FDA Approval For A Landmark Clinical Investigation Of The ATS 3f Aortic Bioprosthesis
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced that the FDA has approved a landmark clinical study in which cardiac surgeons will implant the ATS 3f(R) Aortic Bioprosthesis in a younger aortic valve replacement patient population that has not been previously studied in a controlled and scientific manner. This new FDA approved clinical study will enroll patients younger than 60 years of age, with half of the population younger than 50 years of age. The Company believes that this study will ultimately demonstrate the excellent safety, efficacy and durability of the ATS 3f Aortic Bioprosthesis in this new patient population, while illustrating the performance necessary to maintain the active lifestyle of the younger population.
Risk Of Death Following Acute Coronary Syndromes Different For Men, Women; Attributable To Various Factors
Women may have a slightly higher risk of death than men in the 30 days following an acute coronary syndrome (ACS; such as heart attack or unstable angina ), but this difference appears attributable to factors such as severity and type of ACS, clinical differences and angiographic severity according to a study in the August 26 issue of JAMA. "Cardiovascular disease is the leading cause of death in both men and women, accounting for one-third of all deaths. Although several studies have shown an improvement of prognosis in women over time, overall outcomes remain worse for women compared with men, providing a strong rationale for focusing on the study of sex-based differences in the outcome of acute coronary syndromes, " according to background information in the article.
A new US study found that prostate cancer patients with certain heart conditions who received hormone therapy either before or with radiation therapy were at higher risk of death than equivalent patients who did not have hormone therapy. The study showed that the risk of death nearly doubled for men with coronary artery disease-induced congestive heart failure or heart attack when they received hormone therapy in addition to radiation therapy. The research was done by Akash Nanda of Brigham & Women's Hospital-Dana-Farber Cancer Institute, in Boston, Massachusetts, and colleagues, and appears online in the 26 August issue of JAMA, Journal of the American Medical Association.